Skip to main content

Reyataz Side Effects

Generic name: atazanavir

Medically reviewed by Last updated on Dec 29, 2023.

Note: This document contains side effect information about atazanavir. Some dosage forms listed on this page may not apply to the brand name Reyataz.

Applies to atazanavir: oral capsule, oral powder.

Serious side effects of Reyataz

Along with its needed effects, atazanavir (the active ingredient contained in Reyataz) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking atazanavir:

Incidence not known

Other side effects of Reyataz

Some side effects of atazanavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

Incidence not known

For Healthcare Professionals

Applies to atazanavir: oral capsule, oral powder for reconstitution.


The most common side effects reported in therapy-naive patients during clinical trials were nausea, jaundice/scleral icterus, and rash. The most common side effects reported in therapy-experienced patients during clinical trials were jaundice/scleral icterus and myalgia.[Ref]


Elevated total bilirubin (at least 2.6 times the upper limit of normal [2.6 x ULN]), ALT (at least 5.1 x ULN), and AST (at least 5.1 x ULN) have been reported in up to 53%, up to 25%, and up to 10% of patients, respectively.

Most patients taking this drug experienced asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase. This hyperbilirubinemia was reversible upon discontinuation of this drug.[Ref]

Very common (10% or more): Elevated indirect (unconjugated) bilirubin (up to 87%), elevated total bilirubin (up to 53%), elevated ALT (up to 25%), jaundice (up to 19%)

Common (1% to 10%): Elevated AST, jaundice/scleral icterus

Uncommon (0.1% to 1%): Hepatitis

Rare (less than 0.1%): Hepatosplenomegaly

Frequency not reported: Hepatomegaly, liver damage, acute hepatic cytolysis, biliary lithiasis, choledocholithiasis

Postmarketing reports: Hepatic function abnormalities, cholelithiasis, cholecystitis, cholestasis[Ref]


Elevated total cholesterol (at least 240 mg/dL) and triglycerides (at least 751 mg/dL) have been reported in up to 25% and up to 8% of patients, respectively.[Ref]

Very common (10% or more): Elevated total cholesterol (up to 25%)

Common (1% to 10%): Elevated triglycerides, fever/pyrexia, pain, fatigue, asthenia, lipodystrophy syndrome

Uncommon (0.1% to 1%): Chest pain, malaise, gait disturbances, decreased weight, weight gain

Rare (less than 0.1%): Edema

Frequency not reported: Elevated low-density lipoprotein cholesterol, elevated high-density lipoprotein cholesterol, burning sensation, dysplasia, facial atrophy, generalized edema, heat sensitivity, infection, overdose, pallor, peripheral edema, substernal chest pain, sweating, semicircular canal lithiasis[Ref]


Very common (10% or more): Rash (up to 20%)

Common (1% to 10%): Lipodystrophy

Uncommon (0.1% to 1%): Alopecia, pruritus, urticaria

Rare (less than 0.1%): Vesiculobullous rash, eczema

Frequency not reported: Photosensitivity

Postmarketing reports: Maculopapular rash, erythema multiforme, toxic skin eruptions, drug rash with eosinophilia and systemic symptoms (DRESS) syndrome, angioedema, Stevens-Johnson syndrome[Ref]


Very common (10% or more): Nausea (up to 20%), elevated amylase (up to 14%), elevated lipase (up to 11%)

Common (1% to 10%): Abdominal pain, diarrhea, vomiting, dyspepsia

Uncommon (0.1% to 1%): Dry mouth, flatulence, gastritis, pancreatitis, abdominal distension, aphthous stomatitis

Frequency not reported: Acholia, colitis, constipation, dental pain, esophageal ulcer, gastrointestinal disorder, peptic ulcer, sialolithiasis/parotid gland lithiasis[Ref]

Elevated amylase (at least 2.1 x ULN) and lipase (at least 2.1 x ULN) have been reported in up to 14% and up to 11% of patients, respectively.[Ref]

Nervous system

Very common (10% or more): Headache (up to 14%)

Common (1% to 10%): Peripheral neurological symptoms, dizziness

Uncommon (0.1% to 1%): Syncope, peripheral neuropathy, amnesia, somnolence, dysgeusia

Frequency not reported: Paresthesias[Ref]


Elevated creatine kinase (at least 5.1 x ULN) has been reported in up to 11% of patients.[Ref]

Very common (10% or more): Elevated creatine kinase (up to 11%)

Common (1% to 10%): Back pain, myalgia, arthralgia

Uncommon (0.1% to 1%): Muscle atrophy

Rare (less than 0.1%): Myopathy

Frequency not reported: Bone pain, extremity pain, myasthenia, osteonecrosis[Ref]


Common (1% to 10%): Decreased neutrophils, decreased hemoglobin, decreased platelets

Rare (less than 0.1%): Spontaneous bleeding in hemophiliacs[Ref]

Decreased neutrophils (less than 750 cells/mm3), hemoglobin (less than 8 g/dL), and platelets (less than 50,000 cells/mm3) have been reported in up to 8%, up to 5%, and up to 5% of patients, respectively.[Ref]


Common (1% to 10%): Elevated glucose

Uncommon (0.1% to 1%): Anorexia, increased appetite

Rare (less than 0.1%): Ketoacidosis

Frequency not reported: Hyperkalemia, lactic acidosis, hyperlactatemia, redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance"), hypertriglyceridemia, hypercholesterolemia, insulin resistance

Postmarketing reports: New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, hyperglycemia[Ref]

Elevated glucose (at least 251 mg/dL) has been reported in 5% of patients.[Ref]


Common (1% to 10%): Depression, insomnia

Uncommon (0.1% to 1%): Anxiety, disorientation, sleep disorder, abnormal dream[Ref]


Common (1% to 10%): Scleral icterus/ocular icterus[Ref]


Common (1% to 10%): Increased cough

Uncommon (0.1% to 1%): Dyspnea[Ref]


Uncommon (0.1% to 1%): Hypertension

Rare (less than 0.1%): Palpitation, vasodilatation

Frequency not reported: Prolongation of the PR interval, abnormalities in atrioventricular (AV) conduction, first-degree AV block, prolonged QT interval, ventricular tachycardia, increased QRS interval, heart arrest, heart block, myocarditis

Postmarketing reports: Second-degree AV block, third-degree AV block, left bundle branch block, QTc prolongation, torsades de pointes[Ref]

In healthy volunteers and patients, abnormalities in AV conduction were asymptomatic and generally limited to first-degree AV block.

A 59-year-old HIV-infected woman with congestive heart failure and an ejection fraction of 30% started lamivudine, zidovudine, and atazanavir. One month later, the patient presented with syncope and complained of nausea, which had begun 5 days prior. During the month after therapy initiation, the patient experienced slowly progressive shortness of breath. An ECG showed a QTc interval prolongation of 619 min. Prior to starting antiretroviral therapy, an ECG showed a QTc interval of 398 min for the patient. The patient developed continuous ventricular tachycardia and was defibrillated to sinus bradycardia, which worsened her QT interval prolongation. The patient developed torsades de pointes, which reverted after further defibrillation. Treatment to increase her heart rate and decrease her QT interval was started. The patient's antiretroviral therapy was discontinued during her hospitalization and was not restarted due to concerns regarding QT prolongation. The patient's QTc interval decreased to 394 min and she had no additional ventricular tachyarrhythmias. The patient was restarted on lamivudine, zidovudine, and atazanavir and within 2 days, ECG showed QTc interval prolongation to 571 min. The atazanavir was concluded to be the cause of the prolonged QT interval and torsades de pointes. The patient's QT interval returned to normal following discontinuation of her antiretroviral therapy.[Ref]


An analysis of a ureteral stone determined it was 60% atazanavir (the active ingredient contained in Reyataz) metabolite and 40% calcium phosphate (carbonate apatite). The stone was not metabolites adsorbed into the apatite but contained atazanavir crystals. Analysis of renal calculi from additional patients determined concentrations of atazanavir ranging from 40% to 100%.

Postmarketing reports of chronic kidney disease in HIV-infected patients using this drug (with or without ritonavir) included biopsy-proven cases of granulomatous interstitial nephritis associated with deposition of atazanavir crystals in renal parenchyma.[Ref]

Uncommon (0.1% to 1%): Interstitial nephritis

Rare (less than 0.1%): Acute interstitial nephritis, renal colic, reversible acute renal failure, urolithiasis, kidney pain

Postmarketing reports: Nephrolithiasis, hydronephrosis, renal insufficiency, granulomatous interstitial nephritis, chronic kidney disease[Ref]


Uncommon (0.1% to 1%): Hypersensitivity

Frequency not reported: Allergic reaction[Ref]


Uncommon (0.1% to 1%): Hematuria, frequency of micturition/pollakiuria, proteinuria, gynecomastia

Frequency not reported: Decreased male fertility[Ref]


Frequency not reported: Immune reconstitution syndrome, autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome)[Ref]


1. (2003) "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb

2. EMEA. European Medicines Agency (2007) EPARs. European Union Public Assessment Reports.

3. Croom KF, Dhillon S, Keam SJ (2009) "Atazanavir: A Review of its Use in the Management of HIV-1 Infection." Drugs, 69, p. 1107-40

4. Panel on Antiretroviral Guidelines for Adults and Adolescents (2018) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV

5. Eholie SP, Lacombe K, Serfaty L, Wendum D, Girard PM (2004) "Acute hepatic cytolysis in an HIV-infected patient taking atazanavir." AIDS, 18, p. 1610-1

6. Anderson PL (2004) "Pharmacologic perspectives for once-daily antiretroviral therapy." Ann Pharmacother, 38, p. 1969-70

7. Johnson M, Grinsztejn B, Rodriguez C, et al. (2005) "Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures." AIDS, 19, p. 685-94

8. Rotger M, Taffe P, Bleiber G, et al. (2005) "Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia." J Infect Dis, 192, p. 1381-6

9. Swainston Harrison T, Scott LJ (2005) "Atazanavir: A Review of its Use in the Management of HIV Infection." Drugs, 65, p. 2309-36

10. Johnson M, Grinsztejn B, Rodriguez C, et al. (2006) "96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures." AIDS, 20, p. 711-718

11. Ouagari Z, Tubiana R, Mohand HA, et al. (2006) "Skin rash associated with atazanavir: report of three cases." AIDS, 20, p. 1207-8

12. Cerner Multum, Inc. "UK Summary of Product Characteristics."

13. Piacenti FJ (2006) "An update and review of antiretroviral therapy." Pharmacotherapy, 26, p. 1111-33

14. Hammer SM, Saag MS, Schechter M, et al. (2006) "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA, 296, p. 827-43

15. Colombo S, Buclin T, Cavassini M, et al. (2006) "Population pharmacokinetics of atazanavir in patients with human immunodeficiency virus infection." Antimicrob Agents Chemother

16. Pacanowski J, Poirier JM, Petit I, Meynard JL, Girard PM (2006) "Atazanavir urinary stones in an HIV-infected patient." AIDS, 20, p. 2131

17. van Leeuwen E, Ter Heine R, van der Veen F, Repping S, Beijnen JH, Prins JM (2007) "Penetration of atazanavir in seminal plasma of men infected with HIV-1." Antimicrob Agents Chemother, 51, p. 335-7

18. Rodriguez-Novoa S, Martin-Carbonero L, Barreiro P, et al. (2007) "Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia." AIDS, 21, p. 41-6

19. von Hentig N, Muller A, Rottmann C, et al. (2007) "Pharmacokinetics of saquinavir, atazanavir and ritonavir in a boosted double-protease inhibitor twice-daily regimen." Antimicrob Agents Chemother, 51, p. 1431-9

20. Gatell J, Salmon-Ceron D, Lazzarin A, et al. (2007) "Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results." Clin Infect Dis, 44, p. 1484-92

21. Vernazza P, Daneel S, Schiffer V, et al. (2007) "The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial." AIDS, 21, p. 1309-1315

22. Soriano V, Puoti M, Sulkowski M, et al. (2007) "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS, 21, p. 1073-89

23. Warnke D, Barreto J, Temesgen Z (2007) "Antiretroviral drugs." J Clin Pharmacol, 47, p. 1570-9

24. Guaraldi G, Cocchi S, Motta A, et al. (2008) "A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease." J Antimicrob Chemother, 62, p. 1356-64

25. (2009) "Drugs for HIV infection." Treat Guidel Med Lett, 7, p. 11-22

26. Torti C, Lapadula G, Antinori A, et al. (2009) "Hyperbilirubinemia during atazanavir treatment in 2,404 patients in the Italian Atazanavir Expanded Access Program and MASTER Cohorts." Infection, 37, p. 244-9

27. Jacques AC, Giguere P, Zhang G, Touchie C, la Porte CJ (2009) "Atazanavir-associated choledocholithiasis leading to acute hepatitis in an HIV-infected adult (January)." Ann Pharmacother, 44, p. 202-6

28. Tozzi V (2010) "Pharmacogenetics of antiretrovirals." Antiviral Res, 85, p. 190-200

29. Park WB, Choe PG, Song KH, et al. (2010) "Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency." Clin Infect Dis, 51, p. 101-6

30. Courbon E, Laylavoix F, Soulie C, et al. (2012) "Unexpected atazanavir-associated biliary lithiasis in an HIV-infected patient." J Antimicrob Chemother, 67, p. 250-1

31. Rakotondravelo S, Poinsignon Y, Borsa-Lebas F, et al. (2012) "Complicated atazanavir-associated Cholelithiasis: a Report of 14 Cases." Clin Infect Dis, 55, p. 1270-2

32. Jemsek JG, Arathoon E, Arlotti M, et al. (2006) "Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients." Clin Infect Dis, 42, p. 273-80

33. Pastori D, Esposito A, Cagliuso M, Conti V, Mezzaroma I (2009) "Lithiasis of semicircular canals and parotid glands: unusual stones deposition in atazanavir-treated individuals." AIDS, 23, p. 2233-4

34. Torres HA, Barnett BJ, Arduino RC (2007) "Alopecia associated with ritonavir-boosted atazanavir therapy." AIDS, 21, p. 1391-1392

35. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E (2008) "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother, 62, p. 879-88

36. Le MP, Stitou H, Soulie C, Katlama C, Peytavin G (2012) "Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy." J Antimicrob Chemother, 68, p. 727-9

37. Bergersen BM (2006) "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs, 66, p. 1971-87

38. Ly T, Ruiz ME (2007) "Prolonged QT Interval and Torsades de Pointes Associated with Atazanavir Therapy." Clin Infect Dis, 44, e67-8

39. Gallagher DP, Kieran J, Sheehan G, Lambert J, Mahon N, Mallon PW (2008) "Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports." Clin Infect Dis, 47, e36-8

40. Brewster UC, Perazella MA (2004) "Acute interstitial nephritis associated with atazanavir, a new protease inhibitor." Am J Kidney Dis, 44, e81-4

41. Roling J, Schmid H, Fischereder M, Draenert R, Goebel FD (2006) "HIV-Associated Renal Diseases and Highly Active Antiretroviral Therapy-Induced Nephropathy." Clin Infect Dis, 42, p. 1488-95

42. Chang HR, Pella PM (2006) "Atazanavir urolithiasis." N Engl J Med, 355, p. 2158-2159

43. Anderson PL, Lichtenstein KA, Gerig NE, Kiser JJ, Bushman LR (2007) "Atazanavir-containing renal calculi in an HIV-infected patient." AIDS, 21, p. 1060-2

44. Chan-Tack KM, Truffa MM, Struble KA, Birnkrant DB (2007) "Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System." AIDS, 21, p. 1215-8

45. Couzigou C, Daudon M, Meynard JL, et al. (2007) "Urolithiasis in HIV-positive patients treated with atazanavir." Clin Infect Dis, 45, e105-8

46. Izzedine H, M'rad MB, Bardier A, Daudon M, Salmon D (2007) "Atazanavir crystal nephropathy." AIDS, 21, p. 2357-8

47. Koblic PM, Gold WL, la Porte CJ, Lee TC (2011) "Medication-based urolithiasis and atazanavir." CMAJ, 183, E748-51

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.